---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-026032"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-08-29T23:59:59+00:00"
generated_at: "2026-05-17T09:12:34.738405+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics enters $25M ELOC with White Lion Capital; CFO resigns

## Summary
- Entered $25M equity line with White Lion Capital; commitment period through Aug 29, 2028.
- Pricing options include 97% of lowest price in 2-hour window or 20% discount if price below opening.
- CFO Torsten Hombeck resigns effective Oct 10, 2025; will consult through Nov 30 for transition.
- Company must file S-1 resale registration within 30 days; Exchange Cap at 19.99% of outstanding shares.
- Floor price set at $0.20 per ADS; beneficial ownership limit 4.99% (may increase to 9.99% with notice).

## SEC filing metadata
- accession: 0001641172-25-026032
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-08-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000164117225026032/0001641172-25-026032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000164117225026032/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-026032
- JSON: https://secwatch.observer/filing/0001641172-25-026032.json
- Plain text: https://secwatch.observer/filing/0001641172-25-026032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.